pappas-small-logo

BioAtla Presents Phase 2 Ozuriftamab Vedotin…

SAN DIEGO, June 02, 2025 -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the...
Read More
Investor Login
Pappas CapitalPappas CapitalPappas CapitalPappas Capital
  • Home
  • About 
    • About Us
    • News & Events
    • For Entrepreneurs
    • Contact Us
  • Team
  • Portfolio
  • Ventures
  • Specialized Fund Management 
    • About
    • Chiesi Ventures Fund
    • Asia Innovation Ventures
    • AgTech Initiatives
    • Specialized Holdings
  • Translational Medicine 
    • About
    • Wake Forest Technology Development Program

logo_white
veteran_logo_white
  • Home
  • About
  • Team
  • Portfolio
  • News & Events
  • Contact
  • Ventures
  • Specialized Funds
  • Translational Medicine
NVCA
bio
nc-biotech

© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.

Investor Login
Investor Login

© 2018 Pappas Capital, LLC. ALL RIGHTS RESERVED.